-+ 0.00%
-+ 0.00%
-+ 0.00%

Eledon says updated tegoprubart islet transplant trial data to be presented at ADA 2026 sessions

PUBT·06/04/2026 20:31:48
Listen to the news
Eledon says updated tegoprubart islet transplant trial data to be presented at ADA 2026 sessions
  • Eledon flagged updated results from an investigator-run islet transplant trial of tegoprubart in Type 1 diabetes, scheduled for presentation June 7, 2026.
  • The readout will focus on whether anti-CD40L therapy supported islet graft survival and sustained function, indicating potential to reduce reliance on broader immunosuppression.
  • The presentation keeps tegoprubart in view as Eledon expands its transplant-focused pipeline, supporting strategic optionality across multiple organ and cell-therapy settings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606041631PRIMZONEFULLFEED9732184) on June 04, 2026, and is solely responsible for the information contained therein.